Trial Profile
A Retrospective Chart Review Study of the Outcomes of Second Line Therapy With LEnalidomide/Dexamethasone in Greek Patients With Relapsed/Refractory Multiple MyEloma and the Treatment PatterNs Following Progressive Disease, "The LEGEND Study"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms LEGEND
- Sponsors Genesis Pharma
- 17 Jan 2017 Status changed from recruiting to completed.
- 11 Dec 2015 New trial record